Reaction
Ophthalmic Migraine reporting signals
As of the last recalculation, Ophthalmic Migraine appears in 660 FAERS reports alongside 14 co-occurring drug terms. The strongest observed disproportionality signal is EPTINEZUMAB-JJMR (PRR 24.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Eptinezumab-Jjmr | 7 | 24.5 | 24.5 |
| Rimegepant Sulfate | 9 | 22.7 | 22.7 |
| Voclosporin | 4 | 14.6 | 14.6 |
| Romosozumab-Aqqg | 5 | 11.7 | 11.7 |
| Ofatumumab | 12 | 11.6 | 11.6 |
| Naltrexone Hydrochloride And Bupropion Hydrochloride | 3 | 11.1 | 11.1 |
| Abaloparatide | 10 | 10.9 | 10.9 |
| Siponimod | 3 | 10.6 | 10.7 |
| Avapritinib | 4 | 10.5 | 10.5 |
| Diroximel Fumarate | 3 | 8.0 | 8.0 |
| Cenegermin-Bkbj | 3 | 7.9 | 7.9 |
| Galcanezumab-Gnlm | 6 | 6.1 | 6.1 |
| Tirzepatide | 25 | 5.0 | 5.0 |
| Erenumab-Aooe | 8 | 4.6 | 4.6 |